MA

Q4 2023 update: immuno-oncology related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that immuno-oncology accounted for 14 pharmaceutical deals announced in Q4 2023,…

Q4 2023 update: energy transition related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that energy transition accounted for 3 pharmaceutical deals announced in Q4…

Q4 2023 update: cloud related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that cloud accounted for 3 pharmaceutical deals announced in Q4 2023,…

Q4 2023 update: renewable energy related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that renewable energy accounted for 2 pharmaceutical deals announced in Q4…

Q4 2023 update: easy & affordable related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that easy & affordable accounted for 3 pharmaceutical deals announced in…

Q4 2023 update: remote patient monitoring related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that remote patient monitoring accounted for 3 pharmaceutical deals announced in…

Q4 2023 update: electronic medical record (emr) systems related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that electronic medical record (emr) systems accounted for 2 pharmaceutical deals…

Q4 2023 update: mobile health related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that mobile health accounted for 4 pharmaceutical deals announced in Q4…

Q4 2023 update: cybersecurity related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that cybersecurity accounted for 2 pharmaceutical deals announced in Q4 2023,…

Q4 2023 update: microbiome related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that microbiome accounted for 3 pharmaceutical deals announced in Q4 2023,…